dddaeeca

Daniel Collins

Disclosure: I am in full compliance with all ethics and other policies for Market Realist research analysts. I am not invested in securities that I cover on Market Realist.

More From Daniel Collins

  • uploads///Analysts Reco
    Company & Industry Overviews

    Analysts’ Recommendations for Bristol-Myers Squibb in August 2017

    Of the 23 analysts covering Bristol-Myers Squibb (BMY) in August 2017, six analysts recommended a “strong buy,” and four analysts recommended a “buy.” Ten analysts recommended a “hold,” and three analysts recommended a “sell.”

    By Daniel Collins
  • uploads///Cosentyx
    Company & Industry Overviews

    How Is Novartis’s Cosentyx Positioned after 4Q17?

    In 4Q17, Novartis’s (NVS) Cosentyx generated revenues of $615 million compared to $391 million in 4Q16, which reflected ~57% growth on a year-over-year (or YoY) basis and ~11% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///HIV
    Company & Industry Overviews

    Could Gilead Sciences’ Biktarvy Witness Solid Growth in 2018?

    In February 2018, the US FDA approved Gilead Sciences’ Biktarvy for the treatment of individuals with HIV-1 infection.

    By Daniel Collins
  • uploads///thermometer _
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Merck in September

    Of the 19 analysts tracking Merck (MRK) stock in September, four recommended a “strong buy” while ten analysts recommended a “buy.”

    By Daniel Collins
  • uploads///Analysts
    Company & Industry Overviews

    How Analysts View Johnson & Johnson in October

    On October 18, Johnson & Johnson announced a fourth-quarter cash dividend of $0.90 per share for its common stock.

    By Daniel Collins
  • uploads///teva loss
    Company & Industry Overviews

    Teva Pharmaceutical: Earnings Trends and Recent Developments

    Teva Pharmaceutical’s net income and diluted EPS in the first nine months of 2018 amounted to $541.0 million and $0.53, respectively.

    By Daniel Collins
  • uploads///Diversified products
    Company & Industry Overviews

    Valeant Pharmaceuticals’ U.S. Diversified Products Franchise

    In 1H17, Valeant Pharmaceuticals International’s (VRX) U.S. Diversified Products franchise reported revenues of $519.0 million compared to $848.0 million in 1H17.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for Pfizer in August 2017

    Of the 22 analysts covering Pfizer (PFE) in August 2017, one analyst recommended a “strong buy” and ten analysts recommended a “buy.” On August 26, Pfizer had a consensus 12-month target price of $37.45 for a 12.7% return on investment.

    By Daniel Collins
  • uploads///Taltz
    Company & Industry Overviews

    Eli Lilly’s Immunology Business Saw Solid Growth in 2017

    In 4Q17, Eli Lilly’s (LLY) Taltz generated revenues of $172.5 million compared to $61.3 million in 4Q16.

    By Daniel Collins
  • uploads///Surgery
    Company & Industry Overviews

    A Performance Overview of Johnson & Johnson’s Surgery Segment

    Johnson & Johnson’s (JNJ) Surgery segment reported revenues of $2.4 billion in the third quarter compared to $2.3 billion in the third quarter of 2017.

    By Daniel Collins
  • uploads///Avastin
    Company & Industry Overviews

    A Performance Update for Roche’s Avastin in H2 2018

    In June, the FDA approved Avastin in combination with chemotherapy followed by Avastin monotherapy.

    By Daniel Collins
  • uploads///ecg electrocardiogram stethoscope
    Company & Industry Overviews

    Array BioPharma: Why Wall Street Analysts Are Positive

    Of the eight analysts tracking Array BioPharma in June, three recommended a “strong buy,” while five recommended a “buy.”

    By Daniel Collins
  • uploads///Keytruda
    Company & Industry Overviews

    Merck’s Keytruda Had 80% Growth in the Third Quarter

    Merck & Co.’s (MRK) Keytruda generated revenues of $1.9 billion in the third quarter, reflecting an ~80% YoY growth.

    By Daniel Collins
  • uploads///Pfizer revenues
    Company & Industry Overviews

    How Did Pfizer Perform in 3Q17?

    In 3Q17, Pfizer (PFE) generated revenues of $13.2 billion, an increase of ~1% on a year-over-year (or YoY) basis and a 1% increase on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    What Analysts Recommend for Celgene in 2017

    Celgene (CELG) has a focused and robust clinical pipeline that may help it launch new drugs in the future.

    By Daniel Collins
  • uploads///Featured image
    Company & Industry Overviews

    A Look into Roche Holding’s Performance in Q1 2018

    In Q1 2018, Roche Holding (RHHBY) reported revenues of ~13.6 billion Swiss francs compared to ~12.9 billion Swiss francs in Q1 2017.

    By Daniel Collins
  • uploads///Zimmer biomet revenues
    Company & Industry Overviews

    A Brief Overview of Zimmer Biomet’s Financials

    In Q1 2018, Zimmer Biomet’s (ZBH) revenue grew ~2.3% YoY (year-over-year) to $2.0 billion.

    By Daniel Collins
  • uploads///Biogen Analysts Recommendation
    Company & Industry Overviews

    What Analysts Recommend for Biogen in June 2017

    In 2016, Biogen (BIIB) reported revenues of $11.4 billion, which reflected a ~6% year-over-year (or YoY) growth.

    By Daniel Collins
  • uploads///Tysabri revenues
    Earnings Report

    How 3Q17 Shaped up for Tysabri, Fampyra, and Zinbryta

    Tysabri revenue trends In 3Q17, Biogen’s (BIIB) Tysabri generated revenue of ~$469 million, which reflected a ~9% fall YoY (year-over-year) and a ~5% fall QoQ (quarter-over-quarter). In 3Q17, Tysabri generated US revenue of ~$267 million, which reflected an ~11% fall YoY and an ~8% fall QoQ. In 3Q17, outside the US market, Tysabri reported revenue of ~$203 […]

    By Daniel Collins
  • uploads///Hemlibra
    Company & Industry Overviews

    Roche’s Hemlibra Could Drive Long-Term Growth

    In the first quarter, Roche’s (RHHBY) Hemlibra generated revenues of 23 million Swiss francs.

    By Daniel Collins
  • uploads///BioMarin performance projections
    Company & Industry Overviews

    What to Expect from BioMarin Pharmaceuticals in 2017

    In 2016, BioMarin Pharmaceuticals (BMRN) reported revenues of around $1.1 billion, a ~25% increase year-over-year (or YoY).

    By Daniel Collins
  • uploads///Analysts Rating
    Company & Industry Overviews

    What Analysts Recommend for Bristol-Myers Squibb in November 2017

    23 analysts were tracking Bristol-Myers Squibb in November 2017. Six of them recommended a “strong buy” rating, while four recommended a “buy.”

    By Daniel Collins
  • uploads///feit
    Company & Industry Overviews

    Why Galmed Pharmaceuticals Stock Rose 151% on June 12

    Galmed Pharmaceuticals stock rose 151.3% on June 12. The stock closed at $17.59, which is a 387% increase from its 52-week low of $3.61 on February 14.

    By Daniel Collins
  • uploads///BMRN
    Company & Industry Overviews

    How BioMarin Pharmaceutical Is Positioned Financially in August

    In the second quarter, BioMarin Pharmaceutical (BMRN) reported revenues of $372.8 million compared to $317.4 million in Q2 2017.

    By Daniel Collins
  • uploads///Xalkori Inlyta
    Company & Industry Overviews

    How Are Pfizer’s Xalkori and Inlyta Positioned in 2017?

    In 2016, Pfizer’s (PFE) Xalkori reported revenues of ~$561 million, which reflected a ~15% YoY (year-over-year) rise.

    By Daniel Collins
  • uploads///Xyrem
    Earnings Report

    How Jazz Pharmaceuticals’ Products Performed in 1Q18

    In 1Q18, Jazz Pharmaceuticals’ (JAZZ) Xyrem generated revenue of $316.8 million compared to $272 million in 1Q17.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Novartis on the Street: Analysts’ Recommendations in November

    Of the three analysts tracking Novartis in November 2017, one recommends a “strong buy,” while two recommend a “hold.”

    By Daniel Collins
  • uploads///Vaccine Franchise
    Company & Industry Overviews

    How Merck’s Vaccines Business Is Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Gardasil/Gardasil 9 generated revenues of ~$469 million, which reflected ~19% growth year-over-year and ~12% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Orkambi
    Earnings Report

    How Vertex Pharmaceuticals’ Drugs Performed in 1Q18

    In 1Q18, Vertex Pharmaceuticals’ (VRTX) Orkambi revenue rose ~20% YoY (year-over-year) to $354 million from $295 million.

    By Daniel Collins
  • uploads///molecule _
    Company & Industry Overviews

    Wall Street Analysts: Mostly Positive on Opko Health in July

    On July 11, Opko Health (OPK) stock closed at $6.01, which represents 126% growth from its 52-week low of $2.66 in March.

    By Daniel Collins
  • uploads///Oncology
    Company & Industry Overviews

    A Post-2Q17 Update on Pfizer’s Oncology Drugs: Sutent, Xalkori, and Inlyta

    In 2Q17, Inlyta generated revenues of ~$88 million, which represents an ~19% decline on a YoY basis and ~4% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///CVG
    Company & Industry Overviews

    How Medtronic’s Cardiac and Vascular Group Performed

    Medtronic’s (MDT) Cardiac & Vascular Group generated revenues of $2.9 billion in the second quarter of fiscal 2019 compared to $2.8 billion in the second quarter of fiscal 2018.

    By Daniel Collins
  • uploads///Biogen revenues
    Earnings Report

    How Biogen Performed in 3Q17

    In 3Q17, Biogen (BIIB) generated revenue of ~$3.1 billion, which reflected ~4% growth year-over-year.

    By Daniel Collins
  • uploads///Opko Health analysts
    Earnings Report

    Opko Health: Q2 Expenditures, Developments, Recommendations

    Opko Health’s (OPK) cost of revenues declined from $157.4 million in Q2 2017 to $150.1 million in Q2 2018.

    By Daniel Collins
  • uploads///Xtandi
    Company & Industry Overviews

    What to Expect from Pfizer’s Xtandi in 2018

    In 4Q17, Pfizer (PFE) generated revenues of $168 million from the Xtandi alliance which reflected ~21% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///Stelara
    Company & Industry Overviews

    JNJ’s Stelara Witnessed High Growth in 3Q17

    In 3Q17, Johnson & Johnson’s (JNJ) Stelara generated revenues of $1.1 billion, which reflected ~38% growth on a YoY basis and 14% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Emend Temodar Revenues
    Company & Industry Overviews

    How Merck’s Oncology Drugs Emend and Temodar Could Perform in 2017

    In 2016, Merck’s (MRK) Emend reported revenues of around $549 million, which reflected 3% year-over-year growth.

    By Daniel Collins
  • uploads///cure _
    Company & Industry Overviews

    A Performance Overview of Johnson & Johnson

    Johnson & Johnson, which reported its third-quarter earnings results on October 16, generated net revenue of $20.3 billion in the quarter.

    By Daniel Collins
  • uploads///CNTTF
    Company & Industry Overviews

    CannTrust Holdings’ Stock Grew ~11% Last Week

    On January 25, CannTrust Holdings’ (CNTTF) stock price closed at $6.87, ~5.19% higher than its closing price of $6.53 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///Kisqali BTD
    Company & Industry Overviews

    Novartis Receives 2 Breakthrough Therapy Designations in January

    In January 2018, the FDA granted a BTD to Novartis’s (NVS) Promacta for use along with standard immunosuppressive therapy.

    By Daniel Collins
  • uploads///featured image
    Company & Industry Overviews

    An Overview of Valeant Pharmaceuticals’ Performance in 1Q18

    Valeant Pharmaceuticals (VRX) announced that it would change its name to Bausch Health Companies, which is expected to be effective in July.

    By Daniel Collins
  • uploads///Revlimid revenue
    Company & Industry Overviews

    Revlimid Could Continue to Drive Celgene’s Revenue Growth in 2017

    In 2016, Celgene’s (CELG) Revlimid generated revenues of around $6.9 billion, which reflected a ~20% year-over-year (or YOY) growth.

    By Daniel Collins
  • uploads///Humira Revenues
    Company & Industry Overviews

    Humira May Continue to Drive AbbVie’s Revenue Growth

    In 2016, AbbVie’s (ABBV) drug Humira reported revenue of ~$16.0 billion, which reflected a ~15% year-over-year (or YoY) rise.

    By Daniel Collins
  • uploads///cannabis _
    Company & Industry Overviews

    Why Auxly Cannabis Group Stock Grew ~6.75% on January 25

    On January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth YTD (year-to-date).

    By Daniel Collins
  • uploads///FI
    Company & Industry Overviews

    Why CASI Pharmaceuticals Stock Rose Last Week

    On April 2, 2018, CASI Pharmaceuticals (CASI) stock opened at $4.20. It grew ~68% over the week to close at $7.01 on April 6.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    Januvia and Janument: An Update on Merck’s Diabetes Franchise after 2Q17

    In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Interferon revenues
    Company & Industry Overviews

    Biogen’s Interferon Therapies Could Witness Modest Fall in 2017

    In 2016, Biogen’s (BIIB) interferon therapies, Avonex and Plegridy, together reported revenues of around $2.8 billion, which reflected a drop of ~6% on a year-over-year (or YoY) basis.

    By Daniel Collins
  • uploads///Dupixent
    Company & Industry Overviews

    Regeneron’s Dupixent Approved for Atopic Dermatitis

    In March 2017, the US Food and Drug Administration (FDA) approved Sanofi’s (SNY) and Regeneron Pharmaceuticals’ (REGN) Dupixent (dupilumab) for the treatment of individuals with moderate-to-severe atopic dermatitis.

    By Daniel Collins
  • uploads///Ibrance
    Company & Industry Overviews

    Analyzing Pfizer’s Ibrance and Xalkori after 2Q17

    In the US market in 4Q17, Ibrance generated revenues of $777 million, which reflected ~27% growth on a YoY basis.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Pfizer on the Street: Analyst Recommendations in February 2018

    In January 2017, Pfizer (PFE) and Sangamo Therapeutics (SGMO) entered into a key collaboration agreement.

    By Daniel Collins
  • uploads///blood _
    Company & Industry Overviews

    Zosano Pharma’s Positive Non-Clinical Trial Results

    Today, Zosano Pharma is trading at a stock price of $4.38, which represents ~5.92% growth from its closing price of $4.14 yesterday.

    By Daniel Collins
  • uploads///Virology
    Company & Industry Overviews

    How Merck’s Zepatier and Isentress Are Positioned after 2Q17

    In 2Q17, Merck’s (MRK) Zepatier generated revenues of ~$517 million compared to $112 million in 2Q16.

    By Daniel Collins
  • uploads///II Pipeline
    Company & Industry Overviews

    What’s in Celgene’s Immunology and Inflammation Clinical Pipeline?

    Celgene has entered a strategic collaboration with Acceleron for the development of luspatercept.

    By Daniel Collins
  • uploads///Yescarta
    Company & Industry Overviews

    What Else Could Drive Gilead’s Long-Term Growth?

    In December 2017, Kite, a Gilead Sciences (GILD) company, presented long-term follow-up data from its pivotal ZUMA-1 trial of Yescarta.

    By Daniel Collins
  • uploads///otc_and_api
    Company & Industry Overviews

    Teva Pharmaceutical’s Generic Medicines Segment in 4Q17

    In 4Q17, Teva Pharmaceutical’s (TEVA) generic medicines segment reported revenues of $3.1 billion compared to $3.7 billion in 4Q16.

    By Daniel Collins
  • uploads///Immunology Oncology
    Company & Industry Overviews

    A Look into Merck’s Immunology and Oncology Portfolio

    In 1H17, Remicade generated revenues of around $437 million, which is a 37% decline year-over-year.

    By Daniel Collins
  • uploads///Eliquis and Sprycel
    Company & Industry Overviews

    Eliquis and Sprycel Could Boost BMY’s Revenue Growth in 2H17

    In July 2017, the FDA accepted Bristol-Myers Squibb’s supplemental New Drug Application (or sNDA) for expanding the indication of Sprycel.

    By Daniel Collins
  • uploads///Saxendra
    Company & Industry Overviews

    Novo Nordisk’s Saxendra Could Witness Solid Growth in 2018

    In 4Q17, Novo Nordisk’s (NVO) Saxendra generated revenues of 697 million Danish kroner, which reflected a ~38% YoY growth.

    By Daniel Collins
  • uploads///Nephrology
    Company & Industry Overviews

    How Amgen’s Nephrology Drugs Are Positioned after 2Q17?

    In 2Q17, Amgen’s (AMGN) Aranesp generated revenues of ~$535 million, which represented a 6% year-over-year rise.

    By Daniel Collins
  • uploads///Eylea
    Company & Industry Overviews

    Eylea Could Continue to Generate High Revenue

    Regeneron Pharmaceuticals (REGN) markets Eylea in the United States, and Bayer (BAYZF) commercializes the drug outside the US market.

    By Daniel Collins
  • uploads///Oncology Franchise
    Company & Industry Overviews

    The Latest on TEVA’s Oncology Business

    In 1H17, Teva Pharmaceutical’s (TEVA) oncology business generated revenues of ~$550 million, or ~9% lower YoY (year-over-year).

    By Daniel Collins
  • uploads///Noxafil and Cubicin
    Company & Industry Overviews

    Understanding the Performance of Merck’s Hospital Acute Care Drugs Noxafil and Cubicin

    In 4Q17, Merck’s (MRK) Cubicin reported revenues of $92 million, which was ~23% lower on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///nerve cell _
    Company & Industry Overviews

    Aptinyx Stock Plunged 70% after Clinical Trial Failure

    Today, Aptinyx (APTX) is trading at $5.26, which is a ~70.5% decline from yesterday’s closing price of $17.83.

    By Daniel Collins
  • uploads///Abraxane
    Company & Industry Overviews

    How’s Celgene’s Abraxane Positioned after 4Q17?

    In 4Q17, Celgene’s (CELG) Abraxane generated revenues of $251 million, which reflected a decline of ~6% on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Keytruda
    Company & Industry Overviews

    Merck’s Keytruda Witnessed Solid Growth in First Half of 2018

    In Q2 2018, Merck’s (MRK) Keytruda generated revenues of $1.67 billion compared to $881.0 million in Q2 2017, reflecting ~89% YoY growth.

    By Daniel Collins
  • uploads///Repatha and Blincyto
    Company & Industry Overviews

    Amgen’s Repatha and Blincyto: How They Did in 3Q17

    In 4Q17, Amgen’s (AMGN) Repatha generated revenues of $98 million, which reflected a 69% growth YoY (year-over-year) and a 10% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    What to Expect from Medtronic’s Diabetes Segment

    In September 2018, Medtronic (MDT) announced that the company would acquire all outstanding shares of Mazor Robotics (MZOR) for $58.50 per American depository share.

    By Daniel Collins
  • uploads///Analysts ratings
    Company & Industry Overviews

    Gilead Sciences on the Street in January: Analyst Recommendations

    In December 2017, Gilead Sciences (GILD) and its subsidiary specialized in cell therapy, Kite, entered into an agreement with Cell Design Labs.

    By Daniel Collins
  • uploads///Analysts recommendation
    Company & Industry Overviews

    Analysts Recommendations for AbbVie in August 2017

    Twenty-one analysts were tracking AbbVie in August 2017. Three analysts suggested a “strong buy,” while seven suggested a “buy.”

    By Daniel Collins
  • uploads///Imbruvica
    Company & Industry Overviews

    AbbVie’s Imbruvica in 4Q17 and Fiscal 2017

    AbbVie’s (ABBV) Imbruvica generated revenue of $708 million in 4Q17 and $511 million in 4Q16, reflecting ~39% growth YoY (year-over-year) and ~3% growth quarter-over-quarter.

    By Daniel Collins
  • uploads///Bausch
    Company & Industry Overviews

    A Financial Overview of Bausch Health in October

    Bausch Health’s (BHC) net revenues declined from $4.3 billion in H1 2017 to $4.1 billion in H1 2018, reflecting an ~5.0% year-over-year decline.

    By Daniel Collins
  • uploads///Humira revenues
    Company & Industry Overviews

    AbbVie’s Humira Continues to Generate High Revenues

    In 2Q17, AbbVie’s (ABBV) Humira generated revenues of $4.7 billion, which was a 14.0% rise YoY (year-over-year) and a 15.0% rise QoQ (quarter-over-quarter).

    By Daniel Collins
  • uploads///FI
    Company & Industry Overviews

    What to Expect from Exelixis in 1Q18

    Analysts estimate that in 1Q18, Exelixis will generate revenue of $141.0 million compared to $120.1 million in 4Q17.

    By Daniel Collins
  • uploads///Alkermes
    Company & Industry Overviews

    How’s Alkermes Positioned Financially in September?

    In the second quarter, Alkermes (ALKS) reported revenues of $304.6 million—compared to $218.8 million in the second quarter of 2017.

    By Daniel Collins
  • uploads///syringe __
    Company & Industry Overviews

    Valeant Pharmaceuticals’ Performance in 4Q17 and 2017

    In 4Q17, Valeant Pharmaceuticals (VRX) generated revenues of $2.2 billion compared to $2.4 billion in 4Q16.

    By Daniel Collins
  • uploads///Merck Performance
    Company & Industry Overviews

    How Merck Is Expected to Perform in 2017

    In 1Q17, Merck (MRK) generated revenues of ~$9.4 billion, which reflected 1% YoY growth. Merck expects its GAAP net revenues in fiscal 2017 to reach $39.1 billion–$40.3 billion.

    By Daniel Collins
  • uploads///capsule _
    Company & Industry Overviews

    How Analysts View Amicus Therapeutics in September

    Amicus Therapeutics (FOLD) plans to start the pivotal trial for AT-GAA in the second half of 2018.

    By Daniel Collins
  • uploads///abmd
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive on Abiomed

    On November 26, Abiomed (ABMD) stock closed at $311.15, a ~3.92% rise from its previous day’s close of $299.41 on November 23.

    By Daniel Collins
  • uploads///Pomalyst
    Company & Industry Overviews

    How Celgene’s Pomalyst Is Positioned after 2Q17

    In 2Q17, Celgene’s (CELG) Pomalyst generated revenues of ~$391 million, which reflected ~23% growth on a year-over-year basis.

    By Daniel Collins
  • uploads///human skeleton _
    Earnings Report

    How Exelixis Is Positioned ahead of Its Q2 2018 Earnings Release

    Exelixis (EXEL) is scheduled to report its second-quarter earnings results on August 1.

    By Daniel Collins
  • uploads///Vaccine revenues
    Company & Industry Overviews

    How Pfizer’s Vaccine Franchise Is Positioned in 2017

    In 2016, Pfizer’s (PFE) Prevnar 13 reported revenues of ~$5.7 billion, which reflected a ~8% decline on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///exe
    Earnings Report

    How Did Exelixis Perform in 1Q18?

    In 1Q18, Exelixis (EXEL) generated revenues of $212.3 million, compared to $80.89 million in 1Q17. In 1Q18, Exelixis witnessed ~77% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///virus _
    Company & Industry Overviews

    Analysts Are Mostly Positive on Intellia Therapeutics This Month

    On September 10, Intellia Therapeutics stock closed at $26.98, a ~0.95% fall from the previous day’s close of $27.24.

    By Daniel Collins
  • uploads///Neurociences
    Company & Industry Overviews

    Johnson & Johnson’s Neuroscience Segment in 2017

    In 4Q17, Risperdal Consta generated revenues of $197.0 million, which is an ~6.2% decline on a YoY basis.

    By Daniel Collins
  • uploads///Sterile Injection revenues
    Company & Industry Overviews

    Understanding Pfizer’s Sterile Injection Pharmaceuticals Position in 2017

    In 2016, Pfizer’s (PFE) Medrol reported revenues of ~$450 million, which represented a ~12% rise on a YoY (year-over-year) basis.

    By Daniel Collins
  • uploads///Analysts Ratings
    Company & Industry Overviews

    Analysts’ Recommendations for Amgen in January 2018

    Twenty-six analysts are tracking Amgen in January 2018. Four analysts recommended a “strong buy” while seven analysts recommended a “buy.”

    By Daniel Collins
  • uploads///microbiology Picture
    Company & Industry Overviews

    Wall Street Analysts Are Mostly Positive about Johnson & Johnson

    In June, Johnson & Johnson (JNJ) accepted a binding offer from Platinum Equity to acquire its LifeScan business for ~$2.1 billion.

    By Daniel Collins
  • uploads///Sprycel
    Company & Industry Overviews

    How Is Bristol-Myers Squibb’s Sprycel Positioned Now?

    In 3Q17, Bristol-Myers Squibb’s (BMY) Sprycel generated revenues of $509 million, an 8% increase on a year-over-year (or YoY) basis and ~1% growth on a quarter-over-quarter basis.

    By Daniel Collins
  • uploads///Spectrum
    Company & Industry Overviews

    A Look at Spectrum’s Financial Position in September

    In the second quarter, Spectrum Pharmaceuticals (SPPI) generated net revenues of $24.2 million compared to $34.3 million in Q2 2017.

    By Daniel Collins
  • uploads///pills _
    Company & Industry Overviews

    ContraVir Stock Rose on Clinical Trial Progress Report

    ContraVir Pharmaceuticals is focused on the development of antiviral therapies with a special focus on the development of anti-HBV therapies.

    By Daniel Collins
  • uploads///Diabetes
    Company & Industry Overviews

    An Overview Merck’s Diabetes and Women’s Health Portfolios

    Merck & Company’s (MRK) Januvia reported revenue of $880 million in Q1 2018 compared to $839 million in Q1 2017.

    By Daniel Collins
  • uploads///lab _
    Earnings Report

    How Did Jazz Pharmaceuticals Perform in the Second Quarter?

    Jazz Pharmaceuticals reported revenues of $500.5 million in Q2 2018 compared to $394.4 million in Q2 2017, a ~27% YoY increase and a ~13% sequential increase.

    By Daniel Collins
  • uploads///Analysts recommendation
    Company & Industry Overviews

    What Amgen’s Analysts Recommend in August 2017

    Of the 24 analysts covering Amgen, four have recommended a “strong buy” for the stock, while six have recommended a “buy.”

    By Daniel Collins
  • uploads///Ibrance
    Company & Industry Overviews

    This Drug Is Expected to Be a Significant Driver for Pfizer

    In the first nine months of this year, Pfizer’s (PFE) Ibrance revenue grew 24% YoY (year-over-year) to $3.0 billion from $2.4 billion.

    By Daniel Collins
  • uploads///Net loss
    Company & Industry Overviews

    Analyzing CARA, INSY, and GWPH’s Earnings Trends

    GW Pharmaceuticals’ (GWPH) net income was -$295.2 million in fiscal 2018—compared to -$170.5 million in fiscal 2017.

    By Daniel Collins
  • uploads///brown _
    Company & Industry Overviews

    CARA, INSY, and GWPH: Analysts’ Recommendations in January

    On January 28, Cara Therapeutics’ (CARA) stock price closed at $14.82, which is an ~4.02% discount compared to its previous close.

    By Daniel Collins
  • uploads///cannabis _
    Company & Industry Overviews

    Marijuana Stock iAnthus Capital Already Up ~23% in January

    Today, on the OTC markets, iAnthus Capital Holdings stock (ITHUF) is trading ~3.63% above yesterday’s closing price of $4.84.

    By Daniel Collins
  • uploads///CWBHF
    Company & Industry Overviews

    Charlotte’s Web Holdings’ Stock Grew ~11% Last Week

    On January 25, Charlotte’s Web Holdings’ (CWBHF) stock price closed at $14.41, ~4.87% higher than its closing price of $13.74 on January 24 and ~11% higher than its closing price of $6.21 on January 18.

    By Daniel Collins
  • uploads///herb _
    Company & Industry Overviews

    Innovative Industrial Properties’ Stock Grew ~10% Last Week

    On January 25, Innovative Industrial Properties (IIPR) stock price closed at $59.94, ~3.52% higher than its closing price of $57.90 on January 24 and ~10% higher compared than its closing price of $54.32 on January 18.

    By Daniel Collins
  • uploads///equipment _
    Company & Industry Overviews

    FDA Approves Zimmer Biomet’s ROSA, Stock Up 2.6%

    Today, Zimmer Biomet Holdings’ (ZBH) ROSA Knee System received FDA 510(k) clearance for robotically assisted total knee replacement surgeries.

    By Daniel Collins
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo
    Do Not Sell My Personal Information

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.